hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06269263, orgStudyIdInfo id: 339/23-ek, briefTitle: Pilot Study to Determine Feasibility of Home-based Cardiac Rehabilitation in Patients With Chronic Heart Failure (Pilot-CRHF), acronym: Pilot-CRHF, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-19, primaryCompletionDateStruct date: 2025-02, completionDateStruct date: 2025-02, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: University of Leipzig, class: OTHER, descriptionModule briefSummary: The proposed study will determine the willingness of patients for participation. Furthermore, the assessment of tests to identify eligible patients and the type of exercise intervention that goes along with a high patient compliance is crucial. Also, more information about possible factors preventing patients from participating is required. Therefore, if the patient is willing to participate, we will assess patients' medical history, medication and QoL as well as parameters of routine diagnostics (i.e. echocardiography, laboratory testing, MRI). Following, while the in-patient stay due to cardiac decompensation, we will conduct several assessment-tests to determine the physical status, the exercise capacity and the cognitive function. Moreover, physiotherapists will instruct the patients in the exercise program. After discharge from the hospital, physiotherapist will visit the patient at home to instruct them again in the exercises. Then, the patients will conduct the program on their own for a period of 12 weeks. During the exercise period, a doctoral student will visit the patients at home every 3 weeks to check whether they are doing the exercises correctly and to determine whether there are any problems with the program. After the exercise period of 12 weeks, the baseline characteristics will be assessed again at the University Hospital Leipzig., conditionsModule conditions: Heart Failure, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Pilot study of home-based cardiac rehabilitation, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Home-based cardiac rehabilitation, outcomesModule primaryOutcomes measure: Percentage of patients completing the program, secondaryOutcomes measure: Quality of life, secondaryOutcomes measure: Exercise capacity, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Universitätsklinikum Leipzig, city: Leipzig, state: Saxony, zip: 04103, country: Germany, geoPoint lat: 51.33962, lon: 12.37129, hasResults: False
protocolSection identificationModule nctId: NCT06269250, orgStudyIdInfo id: ANDI-MFA2023_10, briefTitle: Acceptance and Perceived Benefits of Digitalization by Medical Assistants, acronym: ANDI-MFA, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Jacobs University Bremen gGmbH, class: OTHER, collaborators name: Mirjam Jansen; medmedia Academy, descriptionModule briefSummary: The aim of this project is to improve the integration of digital processes, including e-prescriptions, within medical and dental practices for healthcare professionals. Through a better understanding of the obstacles healthcare workers encounter during the adoption of digital processes and their feedback post-implementation, this study will add to the current state of science, contributing to digital process optimization in healthcare., conditionsModule conditions: Health Care Providers, conditions: Patient Safety, conditions: eHealth, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 1000, type: ESTIMATED, armsInterventionsModule interventions name: Policy Change, outcomesModule primaryOutcomes measure: Adoption and acceptance of information technology (IT), primaryOutcomes measure: Requests by patients regarding IT, primaryOutcomes measure: Perceived Benefits of IT, secondaryOutcomes measure: Knowledge and Digital health literacy, secondaryOutcomes measure: Preferred learning format, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Germany, status: RECRUITING, city: Bremen, zip: 28759, country: Germany, contacts name: Sonia Lippke, Prof. Dr., role: CONTACT, phone: +49 421 200 4730, email: slippke@constructor.university, contacts name: Keller Franziska, PhD, role: CONTACT, phone: +49 421 200 4730, email: fkeller@constructor.university, geoPoint lat: 53.07516, lon: 8.80777, hasResults: False
protocolSection identificationModule nctId: NCT06269237, orgStudyIdInfo id: 2023LTA, briefTitle: Point of Care Test of LTA Level in Tear Fluid, Measured With a POCT Test, in DE Patients Following IPL Treatment, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-22, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2024-07-01, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: He Eye Hospital, class: OTHER, descriptionModule briefSummary: To quantify and compare tear levels of Intense pulsed light (IPL) and traditional dry eye clinical tests in dry eye patients before and after Intense pulsed light (IPL) treatment., conditionsModule conditions: Dry Eye, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: M22, interventions name: sham M22, outcomesModule primaryOutcomes measure: LTA, primaryOutcomes measure: Non-invasive tear break-up time (NITBUT), secondaryOutcomes measure: Fluorescein and lissamine conjunctival and cornea staining (CFS), secondaryOutcomes measure: Meibomian quality, secondaryOutcomes measure: Tear Film Lipid Layer Score(TFLL), secondaryOutcomes measure: Tear meniscus height (TMH), secondaryOutcomes measure: Conjunctival hyperemia (RS score), secondaryOutcomes measure: Ocular Surface Disease Index (OSDI), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06269224, orgStudyIdInfo id: HU-FTR-KS-01, briefTitle: Examining Factors Influencing Thoracolumbar Mobility in Runners, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-09-01, primaryCompletionDateStruct date: 2023-01-01, completionDateStruct date: 2024-01-01, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: Hacettepe University, class: OTHER, descriptionModule briefSummary: The presence of to is thoracolumbar (TL) mobility a significant aspect in the context of running. Most of the factors may be related to certain kinematic parameters of the lumbopelvic-hip complex during running., conditionsModule conditions: Runners, conditions: Mobility, conditions: Fascia, conditions: Range of Motion, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 90, type: ACTUAL, armsInterventionsModule interventions name: Participants were recreational runners who run between 20 to 50 km weekly; each one has 35 runners., outcomesModule primaryOutcomes measure: Myoton Assessment, eligibilityModule sex: ALL, minimumAge: 30 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Hacettepe University, city: Ankara, state: Altındağ, zip: 06100, country: Turkey, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False
protocolSection identificationModule nctId: NCT06269185, orgStudyIdInfo id: 2024_IFXvsADAinUC, briefTitle: Comparison Between Infliximab and Adalimumab on Patients With Ulcerative Colitis, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-06, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2025-03-01, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Vastra Gotaland Region, class: OTHER_GOV, descriptionModule briefSummary: Anti-TNF (tumor necrosing factor) treatment with infliximab (IFX) and adalimumab (ADA) are established first-line biological therapies used in treatment of patients with ulcerative colitis (UC). There are no head-to-head comparative studies between these two drug but meta-analysis of randomized controlled trials states that IFX might be more effective than ADA for the induction of clinical remission. However, several observational studies conclude that ADA seem to have similar effect as IFX in treating patients with UC but these studies have limitations.The overall aim of this retrospective multicenter observational cohort study is to evaluate if there is a difference in efficacy between infliximab (IFX) and adalimumab (ADA) in treating bio-naive patients with UC in the short and long term during the modern era when therapeutic drug monitoring have been used to optimize anti-TNF treatment., conditionsModule conditions: Ulcerative Colitis, conditions: Inflammatory Bowel Diseases, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 270, type: ESTIMATED, armsInterventionsModule interventions name: Infliximab, interventions name: Adalimumab, outcomesModule primaryOutcomes measure: Percentage of patients achieving steroid-free clinical remission, secondaryOutcomes measure: Percentage of patients achieving clinical response, secondaryOutcomes measure: Percentage of patients achieving clinical remission, secondaryOutcomes measure: Percentage of patients achieving biochemical remission, secondaryOutcomes measure: Percentage of patients achieving clinical remission, secondaryOutcomes measure: Percentage of patients achieving biochemical remission, secondaryOutcomes measure: Percentage of patients achieving endoscopic response, secondaryOutcomes measure: Percentage of patients achieving endoscopic remission, otherOutcomes measure: Remission rates in the subpopulations of UC-patients with severe, moderate and mild disease respectively, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Västra Götalandsregionen, status: RECRUITING, city: Göteborg, country: Sweden, contacts name: Börje Jonefjäll, role: CONTACT, phone: +46703753933, email: borje.jonefjall@vgregion.se, geoPoint lat: 57.70716, lon: 11.96679, hasResults: False
protocolSection identificationModule nctId: NCT06269172, orgStudyIdInfo id: 162076, secondaryIdInfos id: 322453, type: OTHER, domain: HRA, briefTitle: Perceptions Across Ethnicities to Develop an Adapted Intervention for Breathlessness, acronym: Paint, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-12, primaryCompletionDateStruct date: 2025-11-30, completionDateStruct date: 2025-11-30, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: University Hospitals, Leicester, class: OTHER, descriptionModule briefSummary: An individual's experience of their breathlessness is influenced by multiple factors including their medical condition, psychology, sociological and situational circumstances which will include ethnicity. There is currently a lack of evidence exploring the impact of ethnicity in the experience and presentation of breathlessness.The non-medical management of breathlessness in respiratory diseases includes pulmonary rehabilitation (PR). PR is a highly evidenced exercise-based intervention to help manage breathlessness, improving health-related quality of life and improving survival. Recent audits in England and Wales showed 89% of patients attending PR were recorded as having a White British ethnicity which is in contrast to national ethnicity demographics. This may be because the cultural acceptability of PR components are not fully considered. Therefore, this study will explore how individuals with cardiorespiratory disease from different ethnicities from the Leicestershire population experience and manage their breathlessness through art workshops, focus groups and interviews. Informed by these results, the study team will work with individuals from under-represented ethnicities and key stakeholders to co-design adaptations of PR that may improve the management of breathlessness in underrepresented ethnicities that do not attend conventional PR programmes.The study is funded by the Wellcome Trust as part of the Leicestershire Health Inequalities Improvement Programme at the University of Leiceste, conditionsModule conditions: Cardiovascular Diseases, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: intereviews, outcomesModule primaryOutcomes measure: Art Workshops, Focus Groups and Semi-Structured Interviews, secondaryOutcomes measure: : Experience Based Co-design The co-development of an intervention for breathlessness for under-represented ethnicities., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Glenfield Hospital, status: RECRUITING, city: Leicester, state: Leicestershire, zip: LE39QP, country: United Kingdom, contacts name: Holly Ms Drover, role: CONTACT, email: hd225@leicester.ac.uk, geoPoint lat: 52.6386, lon: -1.13169, hasResults: False
protocolSection identificationModule nctId: NCT06269159, orgStudyIdInfo id: ONZ-2023-0185, briefTitle: The Power of 24-hour: Co-designing Intervention Components, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-09-05, primaryCompletionDateStruct date: 2025-03-31, completionDateStruct date: 2025-03-31, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: University Hospital, Ghent, class: OTHER, descriptionModule briefSummary: Most of the existing lifestyle interventions in adults with overweight or obesity focus on one movement behavior in isolation (i.e. moderate to vigorous physical activity (MVPA)). However, recent research suggests to incorporate all movement behaviors performed in one day to explore the possible synergistic health effects of targeting more than one behavior. Moreover, more optimal 24-hour movement behavior compositions are related with better cardiometabolic health. Literature shows that adults with obesity have less optimal 24-hour compositions (8-9). Therefore it would be of interest to discover the needs related to an optimal 24-hour movement behavior intervention for a group of adults with overweight and obesity using co-design to develop an intervention.This study will conduct a concept mapping protocol to explore the needs to of people with overweight and obesity to change their sedentary behavior into more physical activity as well to include the opinion of health care providers (HCP are physiotherapists) on the needs of their patients., conditionsModule conditions: Overweight and Obesity, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: OTHER, enrollmentInfo count: 210, type: ESTIMATED, armsInterventionsModule interventions name: Concept mapping: brainstorm, interventions name: Concept mapping: clustering and rating, outcomesModule primaryOutcomes measure: Themes, primaryOutcomes measure: Score of effectiveness, primaryOutcomes measure: Score of feasibility, primaryOutcomes measure: Score of modifiability, eligibilityModule sex: ALL, minimumAge: 25 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ghent university Hospital, status: RECRUITING, city: Ghent, zip: 9000, country: Belgium, contacts name: Bruno Lapauw, role: CONTACT, email: bruno.lapauw@uzgent.be, geoPoint lat: 51.05, lon: 3.71667, hasResults: False
protocolSection identificationModule nctId: NCT06269133, orgStudyIdInfo id: R2810-ONC-22115, briefTitle: Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-02-21, primaryCompletionDateStruct date: 2027-03-31, completionDateStruct date: 2027-06-23, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: Regeneron Pharmaceuticals, class: INDUSTRY, descriptionModule briefSummary: This multi-year cohort study will assess the real-world safety and effectiveness of 1L treatment with cemiplimab in combination with platinum-doublet chemotherapy across advanced NSCLC patient subgroups defined by age, sex, race, and ethnicity. Patients will be retrospectively identified from at least two US electronic health record (EHR)-based databases., conditionsModule conditions: Advanced Non-small Cell Lung Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: OTHER, enrollmentInfo count: 1000, type: ESTIMATED, armsInterventionsModule interventions name: REGN2810, interventions name: Platinum-doublet chemotherapy, outcomesModule primaryOutcomes measure: Real-world response rate (rwRR), primaryOutcomes measure: Any treatment-emergent immune-mediated adverse event (imAE), primaryOutcomes measure: Any treatment-emergent imAE resulting in hospitalization, primaryOutcomes measure: Any treatment-emergent imAE resulting in death, primaryOutcomes measure: Specific treatment-emergent imAEs, secondaryOutcomes measure: Real-world duration of response (rwDOR), secondaryOutcomes measure: Real-world progression-free survival (rwPFS), secondaryOutcomes measure: Real-world overall survival (rwOS), secondaryOutcomes measure: Treatment-emergent immune-mediated adverse events (imAEs), secondaryOutcomes measure: Infusion-related reaction (IRR), secondaryOutcomes measure: IRR resulting in hospitalization, secondaryOutcomes measure: IRR resulting in death, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Regeneron Research Facility, city: Tarrytown, state: New York, zip: 10591, country: United States, geoPoint lat: 41.07621, lon: -73.85875, hasResults: False
protocolSection identificationModule nctId: NCT06269120, orgStudyIdInfo id: NN9924-7787, secondaryIdInfos id: U1111-1290-8109, type: OTHER, domain: World Health Organization (WHO), briefTitle: SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-15, primaryCompletionDateStruct date: 2024-09-30, completionDateStruct date: 2024-09-30, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Novo Nordisk A/S, class: INDUSTRY, descriptionModule briefSummary: Participant will get oral semaglutde as prescribed by the study doctor. The study will last for about 26 ± 4 weeks (5 to 7 months). Participant will be asked to complete a questionnaire about how they take oral semaglutide tablets during normal scheduled visit with doctor. Participant will also be asked questions about health and their diabetes treatment and lab tests as part of normal doctor's appointment., conditionsModule conditions: Type 2 Diabetes, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 470, type: ESTIMATED, armsInterventionsModule interventions name: Oral Semaglutide, outcomesModule primaryOutcomes measure: Glycated haemoglobin (HbA1c ) reduction greater than or equal to (≥) 0.5%-point and body weight reduction ≥ 5%, secondaryOutcomes measure: Change in HbA1c, secondaryOutcomes measure: Change in fasting plasm glucose (FPG), secondaryOutcomes measure: Absolute change in body weight (BW), secondaryOutcomes measure: Relative change in BW, secondaryOutcomes measure: HbA1c less than (<) 7.0%, secondaryOutcomes measure: HbA1c <6.5%, secondaryOutcomes measure: Body weight reduction ≥5%, secondaryOutcomes measure: HbA1c reduction ≥1%-point and BW reduction ≥5%, secondaryOutcomes measure: HbA1c reduction ≥1%-point and BW reduction ≥3%, secondaryOutcomes measure: Change in waist circumference, secondaryOutcomes measure: Change in blood pressure (BP) (systolic and diastolic), secondaryOutcomes measure: Change in lipid parameters (total cholesterol, low density lipoprotein cholesterol [LDL-C], high density lipoprotein cholesterol [HDL-C], triglycerides [TG]), secondaryOutcomes measure: Change in high sensitive C-reactive protein (hsCRP), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06269094, orgStudyIdInfo id: MB-2312, briefTitle: A Study to Understand How Continuous Glucose Monitors Impact Eating Behavior, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-14, primaryCompletionDateStruct date: 2024-05, completionDateStruct date: 2024-05, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: Midwest Center for Metabolic and Cardiovascular Research, class: OTHER, descriptionModule briefSummary: The purpose of this study is to evaluate if and how continuous glucose monitors (CGMs) impact food consumption, choice, and purchasing in individuals attempting to lose weight using their own weight management approach., conditionsModule conditions: Weight Loss, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: CGM, outcomesModule primaryOutcomes measure: Qualitative insights on consumer behavior, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Biofortis, Inc., status: RECRUITING, city: Addison, state: Illinois, zip: 60101, country: United States, contacts name: Grace Mooney, MS, role: CONTACT, phone: 630-617-2000, email: grace.mooney@mxns.com, contacts name: Gina Castiglione, RD, role: CONTACT, phone: 6306172000, email: gina.castiglione@mxns.com, contacts name: Aditi M Shah, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 41.9317, lon: -87.98896, hasResults: False